Advertisement

Topics

Avacta losses widen as R&D costs increase

12:17 EDT 16 Apr 2018 | FinanzNachrichten

Biotherapeutics developer Avacta Group released its unaudited interim results for the period ended 31 January on Monday, reporting half-year revenues of £1.5m - up 16% year-on-year - comprising £0....

Original Article: Avacta losses widen as R&D costs increase

NEXT ARTICLE

More From BioPortfolio on "Avacta losses widen as R&D costs increase"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...